Brief: Glaukos Announces Results For Idose TR Exchange Trial

Glaukos

10/01/2023 21:29

Jan 10 (Reuters) - Glaukos Corp  GKOS.N :
    * GLAUKOS ANNOUNCES POSITIVE RESULTS FOR IDOSE TR EXCHANGE
TRIAL,
HIGHLIGHTING FAVORABLE SAFETY AND TOLERABILITY
    * GLAUKOS CORP - RESULTS FROM EXCHANGE TRIAL SHOWED A 2ND
ADMINISTRATION OF IDOSE TR AND REMOVAL OF ORIGINAL IDOSE TR
IMPLANT WAS SAFE, WELL-TOLERATED
    * GLAUKOS CORP - SECOND IDOSE TR DEMONSTRATING A FAVORABLE
SAFETY
PROFILE OVER A 12-MONTH EVALUATION PERIOD
    * GLAUKOS - NO SUBJECT IN EXCHANGE TRIAL EXHIBITED GREATER
THAN
30% ENDOTHELIAL CELL LOSS OVER EXTENDED EVALUATION PERIOD OF
MORE THAN 5 YRS ON AVERAGE
    * GLAUKOS CORP - PLANS TO INCLUDE EXCHANGE TRIAL'S POSITIVE
DATA
SET IN ITS UPCOMING U.S. FDA NEW DRUG APPLICATION SUBMISSION
TARGETED FOR Q1 OF 2023

Source text for Eikon:  ID:nBw8Kl51pa 
Further company coverage:  GKOS.N 
 ((Reuters.Briefs@thomsonreuters.com;))